Arca
Skip to content
Tools
Tools

Systemic scleroderma

Drug research and approvals for systemic scleroderma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 151 studies of systemic scleroderma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 151
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest start dates first, of 151 recruiting on ClinicalTrials.gov ↗

Drug pipeline

3 approved, 10 in phase 3, 30 in phase 2, 8 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Bosentan, Tocilizumab, Nintedanib

Cyclophosphamide anhydrous
Phase 3 DNA inhibitor
Filgrastim
Phase 3 Granulocyte colony stimulating factor receptor agonist
Relaxin
Phase 3
Macitentan
Phase 3 Endothelin receptor, ET-A/ET-B antagonist
Sildenafil
Phase 3 Phosphodiesterase 5A inhibitor
Rosuvastatin
Phase 3 HMG-CoA reductase inhibitor
Inebilizumab
Phase 3 B-lymphocyte antigen CD19 binding agent
Rituximab
Phase 2 B-lymphocyte antigen CD20 binding agent
Mycophenolate mofetil
Phase 2 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Imatinib
Phase 2 Tyrosine-protein kinase ABL inhibitor
Sirolimus
Phase 2 FK506-binding protein 1A inhibitor
Tacrolimus anhydrous
Phase 2 FK506-binding protein 1A inhibitor
Tofacitinib
Phase 2 Janus Kinase (JAK) inhibitor
Belimumab
Phase 2 Tumor necrosis factor ligand superfamily member 13B inhibitor
Pirfenidone
Phase 2 Unknown
Ziritaxestat
Phase 2 Autotaxin inhibitor
Nilotinib
Phase 2 Tyrosine-protein kinase ABL inhibitor
Pomalidomide
Phase 2 CRL4(CRBN) E3 ubiquitin ligase inhibitor
Riociguat
Phase 2 Soluble guanylate cyclase positive allosteric modulator
Clopidogrel
Phase 2 Purinergic receptor P2Y12 antagonist
Human immunoglobulin g
Phase 2 Replacement therapy, immunomodulatory effects
Tadalafil
Phase 2 Phosphodiesterase 5A inhibitor
Iloprost
Phase 2 Prostanoid IP receptor agonist
Plerixafor
Phase 2 C-X-C chemokine receptor type 4 partial agonist
Albumin human
Phase 2 Bilirubin sequestering agent

Showing the 30 furthest along of 48 in trials.

How its trials ended

588 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 129 whose ending is known, 37% met their primary endpoint, 12% missed it and 51% stopped early.

  • Completed, result not reported20635%
  • Ongoing17029%
  • Status unknown8314%
  • Met its primary endpoint488%
  • Stopped: other or unclear336%
  • Stopped: enrollment or feasibility163%
  • Missed its primary endpoint153%
  • Stopped: sponsor or business decision81%
  • Stopped: lack of efficacy61%
  • Stopped: safety20%
  • Stopped: funding10%

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Jul 6, 2017(1'R,6'R)-3-(Benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(p…Treatment of systemic scleroderma (SSc)Emerald Health Pharmaceuticals Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.